These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 7529525)

  • 1. Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay.
    Takada M; Masuda N; Matsuura E; Kusunoki Y; Matui K; Nakagawa K; Yana T; Tuyuguchi I; Oohata I; Fukuoka M
    Br J Cancer; 1995 Jan; 71(1):160-5. PubMed ID: 7529525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study.
    Ebert W; Dienemann H; Fateh-Moghadam A; Scheulen M; Konietzko N; Schleich T; Bombardieri E
    Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):189-99. PubMed ID: 7518259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.
    Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS
    Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role.
    Wieskopf B; Demangeat C; Purohit A; Stenger R; Gries P; Kreisman H; Quoix E
    Chest; 1995 Jul; 108(1):163-9. PubMed ID: 7541742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results?
    Plebani M; Basso D; Navaglia F; De Paoli M; Tommasini A; Cipriani A
    Br J Cancer; 1995 Jul; 72(1):170-3. PubMed ID: 7541234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of serum cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA) as tumour markers for non-small cell lung cancer.
    Chantapet P; Riantawan P; Lebnak P; Getngern P
    J Med Assoc Thai; 2000 Apr; 83(4):383-91. PubMed ID: 10808698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma.
    Huang MS; Jong SB; Tsai MS; Lin MS; Chong IW; Lin HC; Hwang JJ
    Respir Med; 1997 Mar; 91(3):135-42. PubMed ID: 9135852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical usefulness of serum cytokeratin 19 fragment as a tumor marker for lung cancer.
    Maeda Y; Segawa Y; Takigawa N; Takata I; Fujimoto N
    Intern Med; 1996 Oct; 35(10):764-71. PubMed ID: 8933183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of serum tumor markers in patients with lung cancer.
    Hatzakis KD; Froudarakis ME; Bouros D; Tzanakis N; Karkavitsas N; Siafakas NM
    Respiration; 2002; 69(1):25-9. PubMed ID: 11844959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer.
    Lee JH; Chang JH
    Chest; 2005 Oct; 128(4):2298-303. PubMed ID: 16236887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoassay of neuron-specific enolase (NSE) and serum fragments of cytokeratin 19 (CYFRA 21.1) as tumor markers in small cell lung cancer: clinical evaluation and biological hypothesis.
    Giovanella L; Piantanida R; Ceriani L; Bandera M; Novario R; Bianchi L; Roncari G
    Int J Biol Markers; 1997; 12(1):22-6. PubMed ID: 9176714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
    Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
    Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information?
    Nisman B; Lafair J; Heching N; Lyass O; Baras M; Peretz T; Barak V
    Cancer; 1998 May; 82(10):1850-9. PubMed ID: 9587116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of serum CYFRA 21-1 in lung cancer.
    Muraki M; Tohda Y; Iwanaga T; Uejima H; Nagasaka Y; Nakajima S
    Cancer; 1996 Apr; 77(7):1274-7. PubMed ID: 8608502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions.
    Seemann MD; Beinert T; Fürst H; Fink U
    Lung Cancer; 1999 Dec; 26(3):149-55. PubMed ID: 10598925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnostic usefulness of selected tumor markers (CA125, CEA, CYFRA 21-1) in bronchoalveolar lavage fluid in patients with non-small cell lung cancer].
    Dabrowska M; Grubek-Jaworska H; Domagała-Kulawik J; Bartoszewicz Z; Kondracka A; Krenke R; Nejman P; Chazan R
    Pol Arch Med Wewn; 2004 Jun; 111(6):659-65. PubMed ID: 15508787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer.
    Pujol JL; Grenier J; Daurès JP; Daver A; Pujol H; Michel FB
    Cancer Res; 1993 Jan; 53(1):61-6. PubMed ID: 7677981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer.
    Korkmaz ET; Koksal D; Aksu F; Dikmen ZG; Icen D; Maden E; Onder S; Akbiyik F; Emri S
    Clin Biochem; 2018 Aug; 58():15-19. PubMed ID: 29729229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Cyfra 21-1 as a marker for lung cancer.
    Najemnik C; Mohn-Staudner A; Vetter H; Kokron O; Baumgartner G; Scheiner W; Zwick H; Koderhold G; Alth G; Dudczak R
    Wien Klin Wochenschr; 1996; 108(15):467-72. PubMed ID: 8806188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1.
    van der Gaast A; Schoenmakers CH; Kok TC; Blijenberg BG; Cornillie F; Splinter TA
    Br J Cancer; 1994 Mar; 69(3):525-8. PubMed ID: 7510117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.